Lipoprotein Challenges

The discussion highlights the limitations of current treatments, particularly statins, in effectively lowering lipoprotein(a) levels. While statins can successfully reduce LDL cholesterol and APOB, they leave a residual risk when lipoprotein(a) remains elevated. New therapies targeting lipoprotein(a) are essential for addressing this ongoing challenge in lipid management.